Johnson & Johnson has announced an investment of more than US$2 billion to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina. The new facility will expand production of the Company’s portfolio and pipeline of innovative biologics in support of Johnson & Johnson’s broader plan to advance more than 70 novel therapy and product expansion filings and launches by the end of the decade.
“A strong, global supply chain is crucial, and we purposefully invest to ensure our transformational medicines reliably and efficiently reach patients around the world,” said Dapo Ajayi, Vice President, Innovative Medicine Supply Chain, Johnson & Johnson. “We are investing in capacity and new technologies to enhance our industry leading capabilities and ensure a resilient supply chain for the future. North Carolina is an important hub for biopharmaceutical manufacturing and talent, and we are pleased to join this thriving life sciences ecosystem and become part of the Wilson community.”
The new facility will expand production of Johnson & Johnson’s innovative biologic medicines in areas including oncology, immunology and neuroscience, with the latest technology focused on enabling efficient manufacturing operations. When fully operational, the site will employ approximately 420 full-time, highly skilled employees.
Construction is anticipated to begin in the first half of 2025.